Physician profile
Gary Partin
NPI 1386614188
$5,798.06
in general payments reported to CMS, 2019-2025
35 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $464 · 2021: $617 · 2022: $3,132 · 2023: $429 · 2024: $470 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,971.49 | 2021-2025 | |
| Lilly USA, LLC | $485.35 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $449.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $190.89 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.65 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $158.51 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $147.79 | 2019-2023 | |
| Shield Therapeutics INC | $142.45 | 2023-2024 | Accrufer |
| Pfizer INC. | $124.04 | 2019-2025 | |
| Abbott Laboratories | $81.86 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $77.46 | 2019-2022 | |
| Amgen INC. | $76.51 | 2021-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $67.15 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $57.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $52.38 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.06 | 2021-2022 | |
| Melinta Therapeutics, LLC | $41.12 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $38.48 | 2019 | |
| Xeris Pharmaceuticals, INC. | $38.06 | 2022-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $34.70 | 2020 | |
| Lundbeck LLC | $34.19 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.71 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $28.96 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.18 | 2022 | |
| Axsome Therapeutics, INC. | $27.55 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $26.00 | 2024 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $25.07 | 2021 | |
| Allergan, INC. | $23.87 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.79 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.77 | 2021 | |
| Hologic Sales and Service, LLC | $17.04 | 2023 | Aptima |
| Genentech USA, INC. | $16.53 | 2020 | |
| Exact Sciences Corporation | $13.84 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $12.88 | 2022 | |
| Sumitomo Pharma America, INC. | $12.60 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Partin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.